Ocular Therapeutix (OCUL) Misses Q1 EPS by 13c

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.39), $0.13 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $13.37 million versus the consensus estimate of $14.07 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• NVE Corporation names new CEO and expands board to seven members
• Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)